Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
|Articles|September 17, 2012
Quiz on Major Depressive Disorder
Author(s)Psychiatric Times Editors
What are the advantages of adjunctive benzodiazepine therapy in comorbid depression and anxiety? Which therapy has the strongest evidence base for treating patients with late-life depression? These and more in this quiz.
Advertisement
What are the advantages of adjunctive benzodiazepine therapy in comorbid depression and anxiety? Which therapy has the strongest evidence base for treating patients with late-life depression? These and more in this quiz.
Advertisement
Related to this article
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Treating PTSD Among Veterans at Risk for Suicide
2
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
3
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
4
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
5